In a wholly new approach to cancer treatment, Northwestern University biomedical engineers have doubled the effectiveness of ...

A new exploratory analysis of the HIMALAYA phase III trial involving patients with unresectable hepatocellular carcinoma ...

A new study from Professor Vadim Backman shows that restoring cellular memory prevents cancer cells’ ability to adapt to evade treatment.

Progression-free and overall survival were greater in relacorilant plus nab-paclitaxel compared to nab-paclitaxel alone. 2. The rate of adverse events was comparable between groups. Evidence Rating ...

Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...